Silver Book Fact

The combination of information for neuroimaging and circulatory biomarkers could improve both the sensitivity and specificity of pain diagnosis and thereby improve treatment.

Woolf C. Overcoming Obstacles to Developing New Analgesics. Nature Med. 2010; 16(11): 1241-7. http://www.nature.com/nm/journal/v16/n11/full/nm.2230.html

Reference

Title
Overcoming Obstacles to Developing New Analgesics
Publication
Nature Med
Publication Date
2010
Authors
Woolf C
Volume & Issue
Volume 16, Issue 11
Pages
1241-7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.  
  • A meta-analysis of duloxetine, an anti-depressant, found a 50% reduction in pain at 12 weeks for diabetic peripheral neuropathy, and a 50% reduction in pain at 12 weeks for fibromyalgia.  
  • The use of sodium oxybate (SXB) in fibromylagia patients reduced pain by 30% or more in 54-58% of patients (versus 35.2% for placebo). SXB also reduced fatigue and sleep disturbance.  
  • Acupuncture, in combination with routine care, was associated with marked clinical improvements in patients with persistent low back pain. It has also shown improvement in primary and secondary outcomes…